

Un Jung Kang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5253396/publications.pdf>

Version: 2024-02-01

136
papers

10,755
citations

26567

56
h-index

33814

99
g-index

144
all docs

144
docs citations

144
times ranked

11302
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726. | 3.7 | 575 |
| 2 | A Controlled Trial of Rasagiline in Early Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1937. | 4.9 | 559 |
| 3 | Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015, 132, 96-168. | 2.8 | 379 |
| 4 | Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580. | 2.8 | 371 |
| 5 | A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543. | 4.5 | 312 |
| 6 | Natural history and treatment of tardive dystonia. <i>Movement Disorders</i> , 1986, 1, 193-208. | 2.2 | 268 |
| 7 | Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. <i>Journal of Neuroscience</i> , 1995, 15, 7810-7820. | 1.7 | 252 |
| 8 | Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. <i>Molecular Brain Research</i> , 2003, 114, 123-131. | 2.5 | 235 |
| 9 | Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. <i>European Journal of Neuroscience</i> , 2002, 16, 1829-1838. | 1.2 | 224 |
| 10 | Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 21418-21426. | 1.6 | 221 |
| 11 | Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. <i>Neuroscience</i> , 1999, 88, 617-628. | 1.1 | 220 |
| 12 | Characterization of PINK1 processing, stability, and subcellular localization. <i>Journal of Neurochemistry</i> , 2008, 106, 464-474. | 2.1 | 216 |
| 13 | Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice. <i>Journal of Neuroscience</i> , 2008, 28, 425-433. | 1.7 | 211 |
| 14 | A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. <i>Archives of Neurology</i> , 2003, 60, 1721. | 4.9 | 208 |
| 15 | Behavioral models of Parkinson's disease in rodents: A new look at an old problem. <i>Movement Disorders</i> , 2006, 21, 1595-1606. | 2.2 | 200 |
| 16 | Striatal cholinergic interneuron regulation and circuit effects. <i>Frontiers in Synaptic Neuroscience</i> , 2014, 6, 22. | 1.3 | 173 |
| 17 | Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 11. | 2.5 | 169 |
| 18 | Distant effects of locally injected botulinum toxin: A double-blind study of single fiber EMG changes. <i>Muscle and Nerve</i> , 1991, 14, 672-675. | 1.0 | 167 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Enhanced striatal cholinergic neuronal activity mediates DOPA-induced dyskinesia in parkinsonian mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 840-845. | 3.3 | 166 |
| 20 | Spread of symptoms in idiopathic torsion dystonia. <i>Movement Disorders</i> , 1995, 10, 143-152. | 2.2 | 161 |
| 21 | Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2012, 2, 321-331. | 1.5 | 161 |
| 22 | Mitochondrial dysfunction and mitophagy defect triggered by heterozygous <i>GBA</i> mutations. <i>Autophagy</i> , 2019, 15, 113-130. | 4.3 | 155 |
| 23 | Comparative study of cerebrospinal fluid α -synuclein seeding aggregation assays for diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 536-544. | 2.2 | 146 |
| 24 | Expansion of the first PolyA tract of <i>ARX</i> causes infantile spasms and status dystonicus. <i>Neurology</i> , 2007, 69, 427-433. | 1.5 | 143 |
| 25 | Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. <i>Movement Disorders</i> , 1989, 4, 157-175. | 2.2 | 139 |
| 26 | The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. <i>Molecular and Cellular Neurosciences</i> , 2005, 28, 241-252. | 1.0 | 138 |
| 27 | Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. <i>Journal of Neurochemistry</i> , 2006, 97, 1467-1480. | 2.1 | 137 |
| 28 | Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5108-5117. | 3.3 | 136 |
| 29 | Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders</i> , 2020, 35, 711-715. | 2.2 | 134 |
| 30 | Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. <i>Neurology</i> , 2015, 84, 415-420. | 1.5 | 132 |
| 31 | Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018, 33, 282-288. | 2.2 | 122 |
| 32 | Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis of DOPA by Primary Fibroblasts. <i>Journal of Neuroscience</i> , 1996, 16, 4449-4456. | 1.7 | 112 |
| 33 | The Selective Toxicity of 1-Methyl-4-phenylpyridinium to Dopaminergic Neurons: The Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited. <i>Molecular Pharmacology</i> , 2000, 58, 271-278. | 1.0 | 103 |
| 34 | Stromal Cell-Derived Inducing Activity, Nurr1, and Signaling Molecules Synergistically Induce Dopaminergic Neurons from Mouse Embryonic Stem Cells. <i>Stem Cells</i> , 2006, 24, 557-567. | 1.4 | 97 |
| 35 | A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. <i>Journal of Neurosurgery</i> , 2008, 109, 405-409. | 0.9 | 90 |
| 36 | Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. <i>Human Molecular Genetics</i> , 2007, 16, 2900-2910. | 1.4 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Tetrahydrobiopterin Scavenges Superoxide in Dopaminergic Neurons. <i>Journal of Biological Chemistry</i> , 2001, 276, 34402-34407. | 1.6 | 86 |
| 38 | High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 179. | 2.4 | 86 |
| 39 | Effects of Low to Moderate Acute Doses of Pramipexole on Impulsivity and Cognition in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 45-51. | 0.7 | 85 |
| 40 | Dopamine-dependent motor learning: Insight into levodopa's long-duration response. <i>Annals of Neurology</i> , 2010, 67, 639-647. | 2.8 | 85 |
| 41 | Regulation of dopamine production by genetically modified primary fibroblasts. <i>Journal of Neuroscience</i> , 1993, 13, 5203-5211. | 1.7 | 84 |
| 42 | Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1015-1017. | 0.9 | 81 |
| 43 | Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced akt and increased p38 mapk activation, and downregulation of egfr. <i>Glia</i> , 2013, 61, 800-812. | 2.5 | 81 |
| 44 | SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 526-535. | 2.2 | 81 |
| 45 | The Role of Glutathione in Dopaminergic Neuronal Survival. <i>Journal of Neurochemistry</i> , 1997, 69, 1850-1858. | 2.1 | 80 |
| 46 | alpha-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy. <i>Acta Neuropathologica</i> , 2021, 142, 495-511. | 3.9 | 80 |
| 47 | Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. <i>Acta Neuropathologica</i> , 2013, 126, 671-682. | 3.9 | 76 |
| 48 | Phosphorylated alpha-synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7. | 2.4 | 74 |
| 49 | Brain-derived neurotrophic factor-transduced fibroblasts: Production of BDNF and effects of grafting to the adult rat brain. <i>Journal of Comparative Neurology</i> , 1995, 354, 361-376. | 0.9 | 71 |
| 50 | Neural Precursors Derived from Embryonic Stem Cells, but Not Those from Fetal Ventral Mesencephalon, Maintain the Potential to Differentiate into Dopaminergic Neurons After Expansion In Vitro. <i>Stem Cells</i> , 2006, 24, 1583-1593. | 1.4 | 70 |
| 51 | Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis. <i>PLoS ONE</i> , 2017, 12, e0172348. | 1.1 | 69 |
| 52 | Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. <i>Journal of Neurochemistry</i> , 2007, 104, 071018045431005-??? | 2.1 | 68 |
| 53 | Striatal Cholinergic Cell Ablation Attenuates L-DOPA Induced Dyskinesia in Parkinsonian Mice. <i>Journal of Neuroscience</i> , 2014, 34, 3090-3094. | 1.7 | 68 |
| 54 | The role of neuroplasticity in dopaminergic therapy for Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 248-256. | 4.9 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Distinct Mechanisms of Neurodegeneration Induced by Chronic Complex I Inhibition in Dopaminergic and Non-dopaminergic Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 51783-51792. | 1.6 | 63 |
| 56 | Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 49-54. | 1.1 | 61 |
| 57 | Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2007, 27, 11-23. | 2.1 | 59 |
| 58 | Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 663-672. | 0.9 | 57 |
| 59 | Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 989-994. | 0.9 | 56 |
| 60 | Alpha galactosidase A activity in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 112, 85-90. | 2.1 | 56 |
| 61 | In Vivo L-DOPA Production by Genetically Modified Primary Rat Fibroblast or 9L Gliosarcoma Cell Grafts via Coexpression of GTPcyclohydrolase I with Tyrosine Hydroxylase. <i>Experimental Neurology</i> , 1998, 151, 249-264. | 2.0 | 53 |
| 62 | Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice. <i>Autophagy</i> , 2021, 17, 1205-1221. | 4.3 | 53 |
| 63 | Role of Aromatic L-Amino Acid Decarboxylase for Dopamine Replacement by Genetically Modified Fibroblasts in a Rat Model of Parkinson's Disease. <i>Journal of Neurochemistry</i> , 1997, 69, 2055-2063. | 2.1 | 49 |
| 64 | Dopamine neuron glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic interneurons. <i>ELife</i> , 2018, 7, . | 2.8 | 49 |
| 65 | Letters to the editor. <i>Movement Disorders</i> , 1990, 5, 352-355. | 2.2 | 48 |
| 66 | Deduced amino acid sequence of bovine aromatic L-amino acid decarboxylase: homology to other decarboxylases. <i>Molecular Brain Research</i> , 1990, 8, 83-87. | 2.5 | 48 |
| 67 | Unilateral globus pallidus internus stimulation improves delayed onset post-traumatic cervical dystonia with an ipsilateral focal basal ganglia lesion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 588-590. | 0.9 | 48 |
| 68 | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016, 31, 924-932. | 2.2 | 48 |
| 69 | The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. <i>Mitochondrion</i> , 2011, 11, 707-715. | 1.6 | 47 |
| 70 | Frequency of GBA Variants in Autopsy-Proven Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 574-581. | 0.8 | 47 |
| 71 | Vesicular Monoamine Transporter-2 and Aromatic L-Amino Acid Decarboxylase Enhance Dopamine Delivery after L-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats. <i>Journal of Neuroscience</i> , 1999, 19, 3266-3274. | 1.7 | 46 |
| 72 | CSF β -amyloid and risk of freezing of gait in early Parkinson disease. <i>Neurology</i> , 2019, 92, e40-e47. | 1.5 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease. <i>Movement Disorders</i> , 2015, 30, 895-903. | 2.2 | 43 |
| 74 | A case of parkinsonism following striatal lacunar infarction.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1986, 49, 1087-1088. | 0.9 | 41 |
| 75 | Preferential Resistance of Dopaminergic Neurons to the Toxicity of Glutathione Depletion Is Independent of Cellular Glutathione Peroxidase and Is Mediated by Tetrahydrobiopterin. <i>Journal of Neurochemistry</i> , 2002, 74, 2305-2314. | 2.1 | 41 |
| 76 | Cellular replacement therapy for neurologic disorders: potential of genetically engineered cells. <i>Journal of Cellular Biochemistry</i> , 1991, 45, 252-257. | 1.2 | 40 |
| 77 | A rapid α -synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 374-384. | 1.7 | 40 |
| 78 | Structure of the Rat Aromatic L-Amino Acid Decarboxylase Gene: Evidence for an Alternative Promoter Usage. <i>Journal of Neurochemistry</i> , 1993, 60, 1058-1064. | 2.1 | 38 |
| 79 | Loss of PINK1 Attenuates HIF-1 α Induction by Preventing 4E-BP1-Dependent Switch in Protein Translation under Hypoxia. <i>Journal of Neuroscience</i> , 2014, 34, 3079-3089. | 1.7 | 37 |
| 80 | Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia. <i>Neurobiology of Disease</i> , 2015, 76, 67-76. | 2.1 | 37 |
| 81 | Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 357-360. | 0.8 | 37 |
| 82 | SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, . | 2.5 | 36 |
| 83 | Regulation of the Noradrenaline Neurotransmitter Phenotype by the Transcription Factor AP-2 β . <i>Journal of Biological Chemistry</i> , 2008, 283, 16860-16867. | 1.6 | 35 |
| 84 | Adaptation of Stability during Perturbed Walking in Parkinson's Disease. <i>Scientific Reports</i> , 2017, 7, 17875. | 1.6 | 33 |
| 85 | DOPA-decarboxylation in the striata of rats with unilateral substantia nigra lesions. <i>Neuroscience Letters</i> , 1992, 147, 53-57. | 1.0 | 32 |
| 86 | The surfactant poloxamer-188 protects against glutamate toxicity in the rat brain. <i>NeuroReport</i> , 2004, 15, 171-174. | 0.6 | 32 |
| 87 | Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA. <i>ELife</i> , 2020, 9, . | 2.8 | 32 |
| 88 | Structural determinants of PINK1 topology and dual subcellular distribution. <i>BMC Cell Biology</i> , 2010, 11, 90. | 3.0 | 29 |
| 89 | Activity enhances dopaminergic long-duration response in Parkinson disease. <i>Neurology</i> , 2012, 78, 1146-1149. | 1.5 | 26 |
| 90 | Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. <i>Npj Parkinson's Disease</i> , 2015, 1, 15007. | 2.5 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Surfactant poloxamer 188-related decreases in inflammation and tissue damage after experimental brain injury in rats. <i>Journal of Neurosurgery: Pediatrics</i> , 2004, 101, 91-96. | 0.8 | 25 |
| 92 | Poloxamer 188 Volumetrically Decreases Neuronal Loss in the Rat in a Time-dependent Manner. <i>Neurosurgery</i> , 2004, 55, 943-949. | 0.6 | 25 |
| 93 | Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of <sc>Leucine-rich</sc> Repeat Kinase 2 <sc>G2019S</sc> Carriers: A Novel <sc>Enzyme-linked</sc> Immunosorbent Assay-Based Method. <i>Movement Disorders</i> , 2020, 35, 2095-2100. | 2.2 | 24 |
| 94 | Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. <i>Movement Disorders</i> , 2021, 36, 2444-2446. | 2.2 | 24 |
| 95 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82. | 1.5 | 23 |
| 96 | Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats. <i>Journal of Neurosurgery: Pediatrics</i> , 2007, 106, 36-40. | 0.8 | 21 |
| 97 | COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8. | 1.5 | 21 |
| 98 | The Localization and Functional Contribution of Striatal Aromatic L-Amino Acid Decarboxylase to L-3,4-Dihydroxyphenylalanine Decarboxylation in Rodent Parkinsonian Models. <i>Cell Transplantation</i> , 2000, 9, 567-576. | 1.2 | 20 |
| 99 | Identification and Treatment of Cervical and Oromandibular Dystonia in Acutely Brain-Injured Patients. <i>Neurocritical Care</i> , 2005, 3, 139-145. | 1.2 | 20 |
| 100 | Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183. | 1.1 | 20 |
| 101 | The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. <i>Experimental Neurology</i> , 2003, 184, 304-312. | 2.0 | 18 |
| 102 | MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. <i>Brain Research</i> , 2007, 1182, 1-10. | 1.1 | 18 |
| 103 | Letters to the editor. <i>Movement Disorders</i> , 1990, 5, 178-183. | 2.2 | 16 |
| 104 | <sc>mTOR</sc> Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-blind, Placebo-controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. <i>Movement Disorders</i> , 2022, 37, 778-789. | 2.2 | 16 |
| 105 | Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 253-263. | 2.2 | 16 |
| 106 | Transcription factor AP-2 ^β regulates the neurotransmitter phenotype and maturation of chromaffin cells. <i>Molecular and Cellular Neurosciences</i> , 2011, 46, 245-251. | 1.0 | 15 |
| 107 | Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. <i>Brain Research</i> , 2000, 873, 203-211. | 1.1 | 14 |
| 108 | Evoked transients of pH-sensitive fluorescent false neurotransmitter reveal dopamine hot spots in the globus pallidus. <i>ELife</i> , 2018, 7, . | 2.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Effects of repeated waist-pull perturbations on gait stability in subjects with cerebellar ataxia. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2019, 16, 50. | 2.4 | 10 |
| 110 | DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. <i>Neurology</i> , 2014, 82, 636-637. | 1.5 | 9 |
| 111 | Parkinson's Disease Biomarkers: Resources for Discovery and Validation. <i>Neuropsychopharmacology</i> , 2014, 39, 241-242. | 2.8 | 8 |
| 112 | A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats. <i>Journal of Neurochemistry</i> , 2002, 83, 141-149. | 2.1 | 7 |
| 113 | Role of DaTSCAN and clinical diagnosis in Parkinson disease. <i>Neurology</i> , 2012, 79, 1744-1744. | 1.5 | 7 |
| 114 | Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. <i>Neurology</i> , 2015, 85, 557-557. | 1.5 | 7 |
| 115 | Genetic Modification of Cells with Retrovirus Vectors for Grafting into the Central Nervous System. , 1995, , 211-237. | | 7 |
| 116 | Reversibility of Tardive Dyskinesia Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 4, 282. | 1.1 | 7 |
| 117 | Potential of gene therapy for pediatric neurotransmitter diseases: Lessons from Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, S103-S109. | 2.8 | 6 |
| 118 | Exercise Reverses Dysregulation of T-Cell-Related Function in Blood Leukocytes of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 10, 1389. | 1.1 | 6 |
| 119 | Case 1, 1989: Juvenile-onset parkinsonism, dystonia, and pyramidal tract signs. <i>Movement Disorders</i> , 1989, 4, 363-370. | 2.2 | 5 |
| 120 | Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. <i>Movement Disorders</i> , 2015, 30, 1862-1869. | 2.2 | 5 |
| 121 | Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 176-176. | 2.2 | 5 |
| 122 | Intracerebral grafting in the dopaminergic system: issues and controversy. <i>Current Opinion in Neurobiology</i> , 1991, 1, 414-419. | 2.0 | 3 |
| 123 | Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from | | |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Dopamine beta-hydroxylase activity in cerebrospinal fluid of idiopathic torsion dystonia. <i>Neurology</i> , 1990, 40, 1626-1626. | 1.5 | 3 |
| 128 | Reversibility of tardive dyskinesia syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 282. | 1.1 | 3 |
| 129 | Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation. <i>Stroke</i> , 2018, 49, 1977-1980. | 1.0 | 2 |
| 130 | Gene therapy for Parkinson's disease: review and update. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1551-1564. | 1.9 | 1 |
| 131 | Reply To: Detection of Alpha-synuclein in saliva: The importance of preanalytical assessment. <i>Movement Disorders</i> , 2018, 33, 1031-1031. | 2.2 | 1 |
| 132 | Trophic factor delivery by gene therapy. , 0, , 532-547. | | 0 |
| 133 | Biomarkers in neuropsychiatric diseases. <i>Neurobiology of Disease</i> , 2009, 35, 115-116. | 2.1 | 0 |
| 134 | Posters presentation selected for the blue ribbon session at the annual meeting of the Parkinson's disease and movement disorders society (Hong Kong, October, 2018).. <i>Movement Disorders</i> , 2018, 33, 1977-1991. | 2.2 | 0 |
| 135 | Synthes Award for Resident Research in Brain and Craniofacial Injury: poloxamer 188 volumetrically decreases neuron loss in the rat model of excitotoxicity in a time-dependent manner. <i>Clinical Neurosurgery</i> , 2003, 50, 374-81. | 0.2 | 0 |
| 136 | Reply to: Letter on Discussion of Gait Research. <i>Movement Disorders</i> , 2022, 37, 1328-1328. | 2.2 | 0 |